Emerging studies suggest this peptide, a dual activator targeting both GLP-1 and another hormone, may offer a notable step forward for body treatment. Early patient tests have indicated considerable losses in abdominal mass , possibly surpassing current weight-loss therapies . Nevertheless , addi